Diamyd Medical AB Class B
Total Valuation
EURAs of May 31, 2026, Diamyd Medical AB Class B carries a market capitalization of 15.62M, placing it among publicly traded companies globally. Its enterprise value stands at -16.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 15.62M |
| Enterprise Value | -16.55M |
Share Statistics
As of May 31, 2026, Diamyd Medical AB Class B has 154.98M shares outstanding.
| Shares Outstanding | 154.98M |
Valuation Ratios
These figures are as of May 31, 2026.
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
Financial Position
As of May 31, 2026, Diamyd Medical AB Class B maintains a current ratio of 15.50, meaning it holds 15.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.50 |
| Quick Ratio | 15.23 |
Financial Efficiency
These figures cover the twelve months ended May 31, 2026.
| Employee Count | 39.00 |
Stock Price Statistics
EURAs of the close on October 22, 2026, Diamyd Medical AB Class B's stock has declined approximately 90.88% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.45.
| 52-Week Price Change | -90.88% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.45 |
Balance Sheet
EURThese figures are as of May 31, 2026. Total book value stands at 24.11M, with working capital of 30.62M providing operational flexibility.
| Cash & Cash Equivalents | 32.17M |
| Net Debt | -28.48M |
| Equity (Book Value) | 24.11M |
| Book Value Per Share | 0.16 |
| Working Capital | 30.62M |
Cash Flow
EURThese figures cover the twelve months ended May 31, 2026.
| Capital Expenditures | -92,207.27 |
Stock Splits
Diamyd Medical AB Class B's most recent stock split took place on April 10, 2025 with a 429:431 split ratio.
| Last Split Date | 4/10/2025 |
| Split Ratio | 429:431 |